[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Universitario La Fe\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100543263","reduced-stent-strategy-versus-conventional-percutaneous-coronary-revascularization-in-patients-presenting-with-stemi-100543263",false,"NCT06353594","Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI","Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With St-segment Elevation Myocardial Infarction (Copernican)","COPERNICAN","Inclusion Criteria:\n\n\\- Patients presenting with STEMI and indication to undergo pPCI.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year due 1 to non-cardiac disease.\n* Inability to provide informed consent.\n* Cardiogenic shock.\n* Left ventricular ejection fraction \\\u003C15%.\n* Left main disease.\n* Stent thrombosis\n* Patients with prior bypass graft lesions requiring PCI (culprit or non culprit lesions).\n* Patients with chronic total occlusions.\n* Untreatable coronary disease.\n* Non-identified culprit lesion.\n* Known allergy to aspirin, ticagrelor, prasugrel, clopidogrel, paclitaxel or sirolimus.","ALL","18 Years",{"count":20,"type":21},1272,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective is to compare a reduced stent strategy based on drug-coated balloon (DCB) percutaneous coronary intervention (PCI) with conventional drug-eluting stent (DES) coronary revascularization in patients presenting with ST-segment myocardial infarction (STEMI).\n\nRandomization will be performed after successful culprit-lesion guidewire crossing and flow restoration. Random allocation in a 1:1 fashion to one of the following strategies:\n\n* Study group: reduced stent PCI strategy (DCB-based)\n* Control group: conventional PCI strategy (DES-based).",[27],"ST Elevation Myocardial Infarction",[29],"STEMI","RECRUITING","2026-05-25",{"date":33,"type":34},"2026-05-28","ACTUAL",{"date":36,"type":34},"2024-03-11",{"date":38,"type":21},"2035-09",{"name":40,"class":41},"Hospital Universitario La Fe","OTHER",23,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100409823","liver-transplantation-in-patients-with-unresectable-colorectal-liver-metastases-100409823","NCT04616495","Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases","TRASMETIR","Inclusion Criteria:\n\n* ≥ 18 and ≤ years\n* Good performance status, ECOG 0 or 1\n* Resected adenocarcinoma in colon or rectum (R0 resection)\n* Unresectable liver metastases\n* No extrahepatic disease\n* Normal blood tests\n* Response to ≤ 2 lines of chemotherapy (RECIST criteria)\n* ≥ 1 year period since diagnosis of colorectal cancer to enrolment in liver transplant waiting list\n* Signed informed consent\n\nExclusion Criteria:\n\n* Body mass index ≥ 30\n* Positive HIV or HCV\n* Pregnancy at the time of inclusion\n* BRAF mutated status\n* Deterioration of general condition (10% weight loss in the prior 6 months)\n* Other malignancy with disease free survival \\\u003C 5 years\n* Concomitant or prior extrahepatic metastases (histologically or radiologically proved), even if surgically resected.\n* Palliative resection of primary colorectal adenocarcinoma\n* Liver metastases size \\> 5 cm (in the last imaging technique)\n* CEA \\> 80 ng\u002Fml (at time of enrolment in waiting list)\n* No neoadjuvant chemotherapy treatment\n* General contraindication to liver transplantation","65 Years",{"count":52,"type":21},30,"5 Years","OBSERVATIONAL","Multicentric prospective and observational study to assess the 5-year overall survival in a cohort of patients with unresectable liver-only colorectal metastases, well controlled by chemotherapy prior to liver transplantation.",[57,58,59],"Colorectal Cancer","Metastatic Liver Cancer","Liver Metastases","2023-09-21",{"date":62,"type":34},"2023-09-22",{"date":64,"type":34},"2021-09-01",{"date":66,"type":21},"2028-09",{"name":40,"class":41},1,""]